Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer

被引:61
作者
Nucci, M [1 ]
Spector, N [1 ]
Bueno, AP [1 ]
Solza, C [1 ]
Perecmanis, T [1 ]
Bacha, PC [1 ]
Pulcheri, W [1 ]
机构
[1] STATE UNIV RIO DE JANEIRO, RIO DE JANEIRO, BRAZIL
关键词
D O I
10.1093/clind/24.4.575
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To identify the risk factors and attributable mortality associated with superinfections in febrile neutropenic patients with hematologic malignancies, we prospectively evaluated 333 episodes of fever and neutropenia by means of univariate and multivariate analyses. Superinfection was defined as any infection either occurring during antibiotic therapy or developing within 1 week after discontinuation of antibiotic therapy, Of 333 episodes, 46 (13.8%) were defined as superinfection; these episodes occurred in 46 patients. The risk factors for superinfection in the multivariate analysis were longer duration of profound neutropenia (P < .0001), lack of use of quinolones as prophylaxis (P < .0001), presence of a central venous catheter (P = .02), and persistence of fever after 3 days of antibiotic therapy (P = .02), The crude mortality rate among patients with superinfection was 48%, and the attributable mortality rate was 24% (95% confidence interval, 3%-45%). Identifying risk factors for superinfections in neutropenic patients might allow clinical practices to reduce the negative impact of this complication.
引用
收藏
页码:575 / 579
页数:5
相关论文
共 25 条
[1]  
Bodey G P, 1988, Ann N Y Acad Sci, V544, P431, DOI 10.1111/j.1749-6632.1988.tb40441.x
[2]   BETA-LACTUM ANTIBIOTICS ALONE OR IN COMBINATION WITH GENTAMICIN FOR THERAPY OF GRAM-NEGATIVE BACILLARY INFECTIONS IN NEUTROPENIC PATIENTS [J].
BODEY, GP ;
FELD, R ;
BURGESS, MA .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1976, 271 (02) :179-186
[3]   EMPIRICAL ANTIBIOTIC-THERAPY FOR FEVER IN NEUTROPENIC PATIENTS [J].
BODEY, GP .
CLINICAL INFECTIOUS DISEASES, 1993, 17 :S378-S384
[4]   ESCHERICHIA-COLI RESISTANT TO FLUOROQUINOLONES IN PATIENTS WITH CANCER AND NEUTROPENIA [J].
COMETTA, A ;
CALANDRA, T ;
BILLE, J ;
GLAUSER, MP .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (17) :1240-1241
[5]   PREVENTION OF BACTERIAL-INFECTION IN NEUTROPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES - A RANDOMIZED, MULTICENTER TRIAL COMPARING NORFLOXACIN WITH CIPROFLOXACIN [J].
DELFAVERO, A .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (01) :7-12
[6]  
DYBEDAL I, 1989, EUR J HAEMATOL, V42, P405
[7]  
Feld R, 1992, 32 INT C ANT AG CHEM
[8]   FREQUENCY OF BROVIAC CATHETER INFECTIONS IN PEDIATRIC ONCOLOGY PATIENTS [J].
JOHNSON, PR ;
DECKER, MD ;
EDWARDS, KM ;
SCHAFFNER, W ;
WRIGHT, PF .
JOURNAL OF INFECTIOUS DISEASES, 1986, 154 (04) :570-578
[9]   AZTREONAM THERAPY IN NEUTROPENIC PATIENTS WITH CANCER [J].
JONES, PG ;
ROLSTON, KVI ;
FAINSTEIN, V ;
ELTING, L ;
WALTERS, RS ;
BODEY, GP .
AMERICAN JOURNAL OF MEDICINE, 1986, 81 (02) :243-248
[10]   IMPROVED PROGNOSIS FOR GRANULOCYTOPENIC PATIENTS WITH GRAM-NEGATIVE BACTEREMIA [J].
LOVE, LJ ;
SCHIMPFF, SC ;
SCHIFFER, CA ;
WIERNIK, PH .
AMERICAN JOURNAL OF MEDICINE, 1980, 68 (05) :643-648